Delcath Systems Stock News

NEW YORK , May 3, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today

Start Time: 08:30 January 1, 0000 9:00 AM ET Delcath Systems, Inc. (NASDAQ:DCTH ) Q3 2022 Earnings Conference Call November 08, 2022, 08:30 AM ET Company Participants Gerard Michel - CEO Anthony Dias

NEW YORK , Sept. 1, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will particip

Delcath Systems, Inc. (NASDAQ:DCTH ) Q2 2022 Earnings Conference Call August 8, 2022 8:30 AM ET Company Participants David Hoffman - General Counsel Gerard Michel - Chief Executive Officer Anthony Dia

Delcath Systems, Inc. (DCTH) delivered earnings and revenue surprises of -34.09% and 36.49%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

NEW YORK , July 27, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced tod

Here's what you need to know about trading penny stocks on June 7th, 2022 The post What to Know About Buying Penny Stocks on June 7th? appeared first on Penny Stocks to Buy, Picks, News and Informatio

Delcath Systems Ltd. (NASDAQ:DCTH ) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET Company Participants David Hoffman - General Counsel Gerard Michel - Chief Executive Officer Anthony Dias -

Delcath Systems, Inc. (DCTH) delivered earnings and revenue surprises of -19.05% and 70%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Delcath Systems (DCTH) CEO, Gerard Michel on Q4 2021 Results - Earnings Call Transcript

Delcath Systems, Inc. (DCTH) delivered earnings and revenue surprises of 25.81% and 285.38%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the sto

NEW YORK, March 15, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced

NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today that effective March 1, 2022, it will resume direct responsibility for sales, marketing and distribution activities relating to the CHEMOSAT ® Hepatic Delivery System in Europe (EU, United Kingdom, Norway, Liechtenstein, Switzerland). Since December 2018, medac GmbH, a privately held, multi-national pharmaceutical company based in Germany, has been the licensee for CHEMOSAT in Europe. Delcath and medac are working closely together on an orderly transition of activities.

NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced

Delcath Systems Inc (DCTH) shares closed today at 0.6% above its 52 week low of $6.98, giving the company a market cap of $51M. The stock is currently down 9.4% year-to-date, down 56.3% over the past 12 months, and up 1393.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%. Trading Activity Trading volume this week was 18.2% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 7.4% The company's stock price performance over the past 12 months lags the peer average by 6449.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.